![Mark Forman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dr. Mark Forman was previously employed as a Chief Medical Officer by Ventyx Biosciences, Inc., a Chief Medical Officer by Passage Bio, Inc., a Vice President by ACADIA Pharmaceuticals, Inc., and an Executive Director by Translational Medicine Accelerator.
He received his undergraduate degree from Yale University, a doctorate degree from The Rockefeller University and a doctorate degree from Duke University.
| Unternehmen | Position | Ende |
|---|---|---|
| VENTYX BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 04.03.2026 |
| PASSAGE BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 02.08.2024 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01.01.2021 |
Translational Medicine Accelerator | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 7 |
|---|---|
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Rockefeller University
 The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Passage Bio, Inc.
 Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Ventyx Biosciences, Inc.
 Ventyx Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapies for patients with autoimmune, inflammatory and neurodegenerative diseases | Health Technology |
Translational Medicine Accelerator |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
